| Dr Jeremy Andrew Britto, DPM,AACFAS | |
|
3003 New Hyde Park Rd Ste 312, New Hyde Park, NY 11042 | |
| (516) 492-3515 | |
| (516) 492-3516 |
| Full Name | Dr Jeremy Andrew Britto |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 9 Years |
| Location | 3003 New Hyde Park Rd Ste 312, New Hyde Park, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619356466 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Foot And Ankle Surgeons Of Ny Podiatric Surgical, Pllc | 3476984618 | 10 |
| West Village Podiatric Surgical Pc | 5597998997 | 8 |
| Lgd Podiatric Surgical Pc | 8921243890 | 10 |
News Archive
Over the past quarter century in Australia, cancer incidence rates have increased while deaths from cancer have steadily decreased. Those are some of the findings of a recent study published early online in the Asia-Pacific Journal of Clinical Oncology.
Smith & Nephew's (NYSE: SNN) (LSE: SN) Advanced Wound Management division, today announced their platinum sponsorship for the 4th Congress of the World Union of Wound Healing Societies (WUWHS). The meeting will take place in Yokohama, Japan on the 2nd to 7th September 2012. The early commitment to platinum level sponsorship continues the long and successful partnership between Smith & Nephew and the WUWHS.
The feasibility of selecting treatment based on individual molecular characteristics was demonstrated in a first-of-its kind pancreatic cancer clinical trial reported today by the Translational Genomics Research Institute (TGen) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare.
A new controversy is ripe, what with the head of the UK National Health Service (NHS), Simon Stevens, publicly expressing his "serious concerns" about the "fundamentally flawed" practice of homeopathy.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with paclitaxel (Taxol), a standard chemotherapy regimen, will be presented during the 33rd Annual San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2010 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
› Verified 9 days ago
| Provider Name | Lgd Podiatric Surgical Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1245511559 PECOS PAC ID: 8921243890 Enrollment ID: O20130828000690 |
News Archive
Over the past quarter century in Australia, cancer incidence rates have increased while deaths from cancer have steadily decreased. Those are some of the findings of a recent study published early online in the Asia-Pacific Journal of Clinical Oncology.
Smith & Nephew's (NYSE: SNN) (LSE: SN) Advanced Wound Management division, today announced their platinum sponsorship for the 4th Congress of the World Union of Wound Healing Societies (WUWHS). The meeting will take place in Yokohama, Japan on the 2nd to 7th September 2012. The early commitment to platinum level sponsorship continues the long and successful partnership between Smith & Nephew and the WUWHS.
The feasibility of selecting treatment based on individual molecular characteristics was demonstrated in a first-of-its kind pancreatic cancer clinical trial reported today by the Translational Genomics Research Institute (TGen) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare.
A new controversy is ripe, what with the head of the UK National Health Service (NHS), Simon Stevens, publicly expressing his "serious concerns" about the "fundamentally flawed" practice of homeopathy.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with paclitaxel (Taxol), a standard chemotherapy regimen, will be presented during the 33rd Annual San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2010 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
› Verified 9 days ago
| Provider Name | West Village Podiatric Surgical Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1770905911 PECOS PAC ID: 5597998997 Enrollment ID: O20140613000461 |
News Archive
Over the past quarter century in Australia, cancer incidence rates have increased while deaths from cancer have steadily decreased. Those are some of the findings of a recent study published early online in the Asia-Pacific Journal of Clinical Oncology.
Smith & Nephew's (NYSE: SNN) (LSE: SN) Advanced Wound Management division, today announced their platinum sponsorship for the 4th Congress of the World Union of Wound Healing Societies (WUWHS). The meeting will take place in Yokohama, Japan on the 2nd to 7th September 2012. The early commitment to platinum level sponsorship continues the long and successful partnership between Smith & Nephew and the WUWHS.
The feasibility of selecting treatment based on individual molecular characteristics was demonstrated in a first-of-its kind pancreatic cancer clinical trial reported today by the Translational Genomics Research Institute (TGen) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare.
A new controversy is ripe, what with the head of the UK National Health Service (NHS), Simon Stevens, publicly expressing his "serious concerns" about the "fundamentally flawed" practice of homeopathy.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with paclitaxel (Taxol), a standard chemotherapy regimen, will be presented during the 33rd Annual San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2010 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
› Verified 9 days ago
| Provider Name | Foot And Ankle Surgeons Of Ny Podiatric Surgical, Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1861023863 PECOS PAC ID: 3476984618 Enrollment ID: O20200527001368 |
News Archive
Over the past quarter century in Australia, cancer incidence rates have increased while deaths from cancer have steadily decreased. Those are some of the findings of a recent study published early online in the Asia-Pacific Journal of Clinical Oncology.
Smith & Nephew's (NYSE: SNN) (LSE: SN) Advanced Wound Management division, today announced their platinum sponsorship for the 4th Congress of the World Union of Wound Healing Societies (WUWHS). The meeting will take place in Yokohama, Japan on the 2nd to 7th September 2012. The early commitment to platinum level sponsorship continues the long and successful partnership between Smith & Nephew and the WUWHS.
The feasibility of selecting treatment based on individual molecular characteristics was demonstrated in a first-of-its kind pancreatic cancer clinical trial reported today by the Translational Genomics Research Institute (TGen) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare.
A new controversy is ripe, what with the head of the UK National Health Service (NHS), Simon Stevens, publicly expressing his "serious concerns" about the "fundamentally flawed" practice of homeopathy.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with paclitaxel (Taxol), a standard chemotherapy regimen, will be presented during the 33rd Annual San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2010 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jeremy Andrew Britto, DPM,AACFAS 3003 New Hyde Park Rd Ste 312, New Hyde Park, NY 11042-1214 Ph: (516) 492-3515 | Dr Jeremy Andrew Britto, DPM,AACFAS 3003 New Hyde Park Rd Ste 312, New Hyde Park, NY 11042 Ph: (516) 492-3515 |
News Archive
Over the past quarter century in Australia, cancer incidence rates have increased while deaths from cancer have steadily decreased. Those are some of the findings of a recent study published early online in the Asia-Pacific Journal of Clinical Oncology.
Smith & Nephew's (NYSE: SNN) (LSE: SN) Advanced Wound Management division, today announced their platinum sponsorship for the 4th Congress of the World Union of Wound Healing Societies (WUWHS). The meeting will take place in Yokohama, Japan on the 2nd to 7th September 2012. The early commitment to platinum level sponsorship continues the long and successful partnership between Smith & Nephew and the WUWHS.
The feasibility of selecting treatment based on individual molecular characteristics was demonstrated in a first-of-its kind pancreatic cancer clinical trial reported today by the Translational Genomics Research Institute (TGen) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare.
A new controversy is ripe, what with the head of the UK National Health Service (NHS), Simon Stevens, publicly expressing his "serious concerns" about the "fundamentally flawed" practice of homeopathy.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with paclitaxel (Taxol), a standard chemotherapy regimen, will be presented during the 33rd Annual San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2010 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
› Verified 9 days ago
Haleh Nassiri, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 23 Rhodes Dr, New Hyde Park, NY 11040 Phone: 925-330-7366 | |
Joseph Alencherry, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 3003 New Hyde Park Rd, Suite 312, New Hyde Park, NY 11042 Phone: 516-492-3515 Fax: 516-492-3516 | |
Jack Levenson, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 3003 New Hyde Park Rd Ste 312, New Hyde Park, NY 11042 Phone: 516-492-3515 | |
Dr. Gino Scartozzi, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 2 Aberdeen Rd, New Hyde Park, NY 11040 Phone: 516-326-7936 Fax: 516-326-8139 | |
Gail Frances Garofalo, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 410 Lakeville Rd, Suite 303, New Hyde Park, NY 11042 Phone: 516-326-4709 Fax: 516-326-8968 | |
Thomas Barbaro D.p.m. P.c. Podiatrist Medicare: Medicare Enrolled Practice Location: 706 Jericho Tpke, New Hyde Park, NY 11040 Phone: 516-326-7979 Fax: 516-437-8588 | |
Dr. Sumit Shailesh Dharia, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 100 Wilson Blvd, New Hyde Park, NY 11040 Phone: 516-359-3339 Fax: 718-567-1774 |